Preferred Label : Anti-CD73 Monoclonal Antibody IBI325;
NCIt definition : A monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation
73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and
antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody IBI325
targets and binds to CD73 on tumor cells, thereby inhibiting the activity of CD73.
This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP)
to adenosine and the adenosine-mediated suppression of lymphocyte activity and trafficking.
This attenuates the adenosine-induced immunosuppression in tumor microenvironment
(TME), increases the activity of cytotoxic T-lymphocytes (CTLs), activates macrophages
and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory
T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and
enhancing the CTL-mediated immune response against cancer cells, tumor cell growth
is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase)
family, is upregulated on a number of cancer cell types and catalyzes the conversion
of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such
as adenosine; it plays a key role in adenosine-mediated immunosuppression within the
TME.;
Molecule name : IBI 325; IBI-325;
NCI Metathesaurus CUI : CL1773821;
Origin ID : C185394;
UMLS CUI : C5666977;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
